Nivolumab and Recombinant Human Hyaluronidase clinical trials
Also written BMS-986298.
A product of Nivolumab; its studies count on that page too.
How each study uses Nivolumab and Recombinant Human Hyaluronidase has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 27 Dec 2024 · OPDIVO QVANTIG · BLA 761381 (FDA, Drugs@FDA)
- European Union
- 19 Jun 2015 · Opdivo · EMEA/H/C/003985 (EMA; as Nivolumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Nivolumab source
- One of Immune checkpoint inhibitors source
Studies
Open first, then newest update. How each study uses Nivolumab and Recombinant Human Hyaluronidase has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingPhase 3Bristol-Myers SquibbNCT04810078On the US labelWritten as Nivolumab and rHuPH20Report a problem
- A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedPhase 3Bristol-Myers SquibbNCT05297565Written as Nivolumab/rHuPH20Report a problem
- A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnPhase 2Bristol-Myers SquibbNCT05496192Written as Nivolumab/rHuPH20Report a problem
Behind its US label · 24 — the studies the FDA label of OPDIVO QVANTIG describes
From the Clinical Studies section of OPDIVO QVANTIG (2026-05), as openFDA has it. A study the site does not hold is left out.
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedPhase 3Bristol-Myers SquibbNCT01642004Report a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT01658878Report a problem
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedPhase 3Bristol-Myers SquibbNCT01668784Report a problem
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedPhase 3Bristol-Myers SquibbNCT01673867Report a problem
- A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedPhase 3Bristol-Myers SquibbNCT01721746Report a problem
- Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT01721772Report a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedPhase 3Bristol-Myers SquibbNCT01844505Report a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188Report a problem
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)CompletedPhase 3Bristol-Myers SquibbNCT02105636Report a problem
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedPhase 3Bristol-Myers SquibbNCT02231749Report a problem
- A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCompletedPhase 2Bristol-Myers SquibbNCT02387996Report a problem
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedPhase 3Bristol-Myers SquibbNCT02388906Report a problem
- Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerCompletedPhase 3Ono Pharmaceutical Co. LtdNCT02569242Report a problem
- An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerCompletedPhase 3Bristol-Myers SquibbNCT02632409Report a problem
- An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerCompletedPhase 3Bristol-Myers SquibbNCT02743494Report a problem
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCompletedPhase 3Bristol-Myers SquibbNCT02872116Report a problem
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Bristol-Myers SquibbNCT02998528Report a problem
- Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerCompletedPhase 3Bristol-Myers SquibbNCT03036098Report a problem
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT03141177Report a problem
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedPhase 3Bristol-Myers SquibbNCT03143153Report a problem
- A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingPhase 3Bristol-Myers SquibbNCT04025879Report a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607Report a problem
- Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT04099251Report a problem
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingPhase 3Bristol-Myers SquibbNCT04810078Report a problem
Tested with established drugs · 2 — they are given beside it
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingPhase 3Bristol-Myers SquibbNCT04810078On the US labelWritten as Nivolumab and rHuPH20Report a problem
- A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedPhase 3Bristol-Myers SquibbNCT05297565Written as Nivolumab/rHuPH20Report a problem